US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biomarin Pharmaceutical

67.48

-0.8400-1.23%

Post-market: 67.590.1100+0.16%18:11 EDT

Volume:1.83M

Turnover:124.17M

Market Cap:12.87B

PE:30.57

High:68.54

Open:67.83

Low:67.28

Close:68.32

Loading ...

Overview Company News Filings

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies

NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study

PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study

BEAM Down Despite Positive Initial Data From Genetic Disorder Study

KOD Completes Enrollment in Phase III Study for Eye Disease Candidate

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

Teladoc Boosts Weight Care Access With LillyDirect, Aids Growth

INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies

EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC

LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study

4 Discounted PEG Stocks Offering the Best Returns to Value Investors

Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?

PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy

Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio

Teladoc Health Enhances Prism Platform for Better Virtual Care

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

BioMarin Pharmaceutical (BMRN) Receives a Buy from TD Cowen

Statutory Profit Doesn't Reflect How Good BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings Are

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BMRN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BMRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMRN\",,,,,undefined,":{"symbol":"BMRN","market":"US","secType":"STK","nameCN":"Biomarin Pharmaceutical","latestPrice":67.48,"timestamp":1743710400000,"preClose":68.32,"halted":0,"volume":1833698,"hourTrading":{"tag":"盘后","latestPrice":67.59,"preClose":67.48,"latestTime":"18:11 EDT","volume":49747,"amount":3357129.53282,"timestamp":1743718307471},"delay":0,"floatShares":178454323,"shares":190777052,"eps":2.207261,"marketStatus":"Post-Market Trading","change":-0.84,"latestTime":"04-03 19:33:07 EDT","open":67.83,"high":68.54,"low":67.28,"amount":124170987.15968001,"amplitude":0.018443,"askPrice":68.73,"askSize":16,"bidPrice":64.11,"bidSize":20,"shortable":3,"etf":0,"ttmEps":2.207261,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743724800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":932702400000,"exchange":"NASDAQ","adjPreClose":68.32,"preHourTrading":{"tag":"盘前","latestPrice":67.83,"preClose":68.32,"latestTime":"09:29 EDT","volume":4329,"amount":286076.20743,"timestamp":1743686999999},"postHourTrading":{"tag":"盘后","latestPrice":67.59,"preClose":67.48,"latestTime":"18:11 EDT","volume":49747,"amount":3357129.53282,"timestamp":1743718307471},"volumeRatio":1.308711,"impliedVol":0.4149,"impliedVolPercentile":0.9641},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMRN\",,,,,undefined,":{"symbol":"BMRN","floatShares":178454323,"roa":"5.15%","roe":"8.05%","lyrEps":2.246307,"volumeRatio":1.308711,"shares":190777052,"dividePrice":0,"high":68.54,"amplitude":0.018443,"preClose":68.32,"low":67.28,"week52Low":60.63,"pbRate":"2.28","psRate":"4.51","week52High":94.85,"institutionHeld":0.9275,"latestPrice":67.48,"committee":0.111111,"eps":2.207261,"divideRate":0,"volume":1833698,"delay":0,"ttmEps":2.207261,"open":67.83,"prevYearClose":65.73,"prevWeekClose":71.44,"prevMonthClose":70.69,"prevQuarterClose":70.69,"fiveDayClose":72.83,"twentyDayClose":71.21,"sixtyDayClose":67.07},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMRN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520157674","title":"Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2520157674","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520157674?lang=en_us&edition=fundamental","pubTime":"2025-03-17 21:45","pubTimestamp":1742219110,"startTime":"0","endTime":"0","summary":"Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.Why This 1 Growth Stock Should Be On Your Watchlist. Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time.Nine analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.30 to $","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-biomarin-pharmaceutical-bmrn-134510442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BMRN","IE00B7SZLL34.SGD","IE0002270589.USD","BK4139"],"gpt_icon":0},{"id":"2520576748","title":"AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2520576748","media":"Zacks","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520576748?lang=en_us&edition=fundamental","pubTime":"2025-03-17 21:38","pubTimestamp":1742218680,"startTime":"0","endTime":"0","summary":"AstraZenecaAZN announced that it has entered into a definitive agreement to acquire EsoBiotec for developing in vivo cell therapies for multiple cancer indications or immune-mediated diseases. EsoBiotec is a biotechnology company specializing in “in vivo” cell therapies with promising early clinical results.The acquisition will integrate EsoBiotec’s proprietary ENaBL platform, which empowers the immune system’s ability to target cancers, into AstraZeneca’s portfolio. This technology has the potential to expand patient access to transformative cell therapy treatments, delivering results in minutes instead of the current weeks-long process. The deal will allow EsoBiotec to leverage AZN’s vast resources and expertise in cell therapies to accelerate the development of their in vivo platform which has a novel delivery technology that is expected to have broad therapeutic applicability.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/azn-acquire-esobiotec-1b-develop-133800753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2087621335.USD","BK4583","LU1559883803.SGD","BK4566","BK4550","GILD","LU2468319806.SGD","LU0109394709.USD","LU0320765992.SGD","BK4568","BK4532","IE00B19Z3581.USD","BK4585","LU0566484027.USD","BMRN","IE00BKVL7J92.USD","LU0234570918.USD","LU1829250122.USD","CORT","IE00B3T34201.USD","BK4588","IE00B19Z3B42.SGD","LU1571399168.USD","LU0889565916.HKD","LU2236285917.USD","LU0058720904.USD","IE0002270589.USD","LU1585245621.USD","LU0289739699.SGD","BK4139","LU1430594728.SGD","LU2089984988.USD","LU2462157665.USD","AZN","LU1066051498.USD","IE00BZ1G4Q59.USD","BK4578","LU2456880835.USD","BK4007","IE00B7SZLL34.SGD","LU1066053197.SGD","LU2417539215.USD","LU1839511570.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2518477984","title":"NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2518477984","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518477984?lang=en_us&edition=fundamental","pubTime":"2025-03-12 01:51","pubTimestamp":1741715460,"startTime":"0","endTime":"0","summary":"Novo Nordisk NVO has achieved the primary endpoint in the second late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema, in patients with obesity and type 2 diabetes  and a mean baseline body weight of 102 kg. The results showed that treatment with the candidate led to a statistically significant and superior weight loss at week 68compared with placebo.NVO’s CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and Wegovy. The two molecules promote weight loss by suppressing hunger, enhancing feelings of fullness and helping individuals consume fewer calories.The phase III REDEFINE 2 study followed a flexible protocol, enabling patients to adjust their dosing throughout the study. After 68 weeks, 61.9% of those treated with CagriSema reached the highest dose.Novo Nordisk plans to submit a regulatory application seeking the first approval for CagriSema for the obesity indication in the first quarter of 2026. Det","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvo-stock-down-9-cagrisema-175100065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4583","LU0234570918.USD","IE00B19Z3581.USD","LU0566484027.USD","LU0154236417.USD","BK4007","GILD","IE0002270589.USD","IE00BKVL7J92.USD","LU0058720904.USD","LU2087621335.USD","LU1585245621.USD","IE00BSNM7G36.USD","BK4566","LU1066053197.SGD","LU0889565916.HKD","CORT","BK4532","IE00B19Z3B42.SGD","LU2468319806.SGD","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4568","LU0320765992.SGD","LU0289739699.SGD","LU1093756325.SGD","IE00B3T34201.USD","IE00B7SZLL34.SGD","BK4550","BMRN","LU1559883803.SGD","LU0109394709.USD","LU2089984988.USD","BK4585","BK4588","LU1839511570.USD","BK4578","LU1571399168.USD","BK4599","NVO","LU1430594728.SGD","LU1066051498.USD","BK4139"],"gpt_icon":1},{"id":"2518727781","title":"PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2518727781","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518727781?lang=en_us&edition=fundamental","pubTime":"2025-03-12 00:15","pubTimestamp":1741709700,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics, Inc. PTGX announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated icotrokinra , an investigational targeted oral peptide that selectively blocks the IL-23 receptor, for treating adults with moderately to severely active ulcerative colitis , a chronic disease of the large intestine.The ANTHEM-UC study, conducted by Protagonist's partner, Johnson & Johnson JNJ, met its primary endpoint of clinical response in all icotrokinra dose groups.Treatment with icotrokinra also demonstrated clinically meaningful differences in key secondary endpoints of clinical remission, symptomatic remission and endoscopic improvement at week 12 versus placebo in the ANTHEM-UC study.Shares of PTGX were up 45.9% on March 10 following the announcement of the news.In the past year, shares of Protagonist have rallied 87.4% against the industry’s decline of 8.5%.The randomized, placebo-controlled phase IIb ANTHEM-UC study evaluated the safety and efficacy of thr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ptgx-j-j-partnered-drug-161500020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2125154778.USD","LU0792757196.USD","LU2360032135.SGD","BMRN","LU2347655156.SGD","IE00BGHQF631.EUR","BK4592","LU0795875086.SGD","LU2125154935.USD","LU2133065610.SGD","LU1291159041.SGD","BK4581","LU1221951046.USD","SG9999002232.USD","BK4585","IE00BFXG1179.USD","LU2468319806.SGD","LU0203347892.USD","LU1066051498.USD","IE00B4R5TH58.HKD","LU0345770993.USD","LU1914381329.SGD","LU1868836591.USD","LU1244550577.SGD","LU1732800096.USD","BK4534","BK4588","LU1929549753.HKD","IE0034235303.USD","LU1061106388.HKD","LU1674673428.USD","LU1023059063.AUD","LU0640476718.USD","BK4007","BK4532","BMY","LU1244550221.USD","LU2129689431.USD","PTGX","LU2430703178.SGD","IE000M9KFDE8.USD","LU1323610961.USD","LU2602419157.SGD","IE00B42XCP33.USD","LU1989771016.USD","IE00BVYPNV92.GBP","IE00B2B36J28.USD","LU0098860793.USD","JNJ","LU1585245621.USD"],"gpt_icon":0},{"id":"2518272677","title":"BEAM Down Despite Positive Initial Data From Genetic Disorder Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2518272677","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518272677?lang=en_us&edition=fundamental","pubTime":"2025-03-12 00:07","pubTimestamp":1741709220,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Inc. BEAM announced positive initial safety and efficacy data from a phase I/II study, which is evaluating its pipeline candidate, BEAM-302, for treating patients with alpha-1 antitrypsin deficiency .Currently, there are no approved curative treatments for the given indication.Data from the study showed that treatment with a single dose of BEAM-302 demonstrated durable, dose-dependent increases in total and functional alpha-1 antitrypsin . Also, new production of corrected protein  and decreases in toxic mutant Z-AAT were observed in circulation across the initial three doses.All three patients treated with BEAM-302  achieved a mean total AAT of 12.4M at day 28, exceeding the 11M protective therapeutic threshold. Also, treatment with BEAM-302  reduced mutant Z-AAT up to 78%.The initial safety finding suggests that treatment with BEAM-302 was well tolerated across all dose levels, leading to durable dose-dependent correction of the disease-causing mutation.Despite the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-down-despite-positive-initial-160700470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XNCR","BK4585","IE00B19Z3B42.SGD","BK4566","BK4139","BK4611","IE00B7SZLL34.SGD","BK4505","BK4160","ANIX","AAT","BK4588","BK4535","BK4556","IE00B19Z3581.USD","BMRN","BEAM","IE0002270589.USD"],"gpt_icon":0},{"id":"2518072238","title":"KOD Completes Enrollment in Phase III Study for Eye Disease Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2518072238","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518072238?lang=en_us&edition=fundamental","pubTime":"2025-03-11 22:39","pubTimestamp":1741703940,"startTime":"0","endTime":"0","summary":"Kodiak SciencesKOD announced that it has completed enrollment in a late-stage study of tarcocimab tedromer in patients with diabetic retinopathy . Per KOD, more than 250 patients have been enrolled in the phase III GLOW2 study, surpassing the initial enrollment target. With a 48-week treatment duration, all patients are expected to complete their primary endpoint visits by the end of January 2026. The top-line clinical data is anticipated to be announced in the first quarter of 2026.In late 2023, Kodiak rebooted the development program of tarcocimab following positive phase III results from the GLOW1 study, which evaluated the treatment in patients with moderately severe to severe non-proliferative diabetic retinopathy. Leveraging the GLOW1 study's success, Kodiak initiated the GLOW2 study to further investigate tarcocimab for DR and began dosing patients in May 2024. Enrolled DR patients will receive tarcocimab on extended dosing intervals, including six-month dosing for all patients.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kod-completes-enrollment-phase-iii-143900570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0889565916.HKD","GILD","LU2458330243.SGD","BK4578","BK4612","IE00B19Z3B42.SGD","LU0320765992.SGD","LU2098885051.SGD","IE00BSNM7G36.USD","LU0082616367.USD","IE00B3T34201.USD","LU0719512351.SGD","LU1880398554.USD","LU0056508442.USD","CORT","LU1839511570.USD","LU1951198990.SGD","IE0009356076.USD","LU0642271901.SGD","LU2089984988.USD","LU2250418816.HKD","BK4585","BK4573","BMRN","LU0109394709.USD","LU1923623000.USD","LU2468319806.SGD","BK4554","LU2054465674.USD","LU0127658192.USD","LU0390134368.USD","III","LU0889565833.HKD","LU1066051498.USD","LU2458330169.SGD","BK4614","IE00B19Z3581.USD","BK4583","LU1951200564.SGD","BK4575","LU0823434583.USD","LU1803068979.SGD","LU1988902786.USD","BK4141","LU2360106780.USD","LU1559883803.SGD","KOD","LU1316542783.SGD","BK4550"],"gpt_icon":1},{"id":"2518745099","title":"PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2518745099","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518745099?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:05","pubTimestamp":1741691100,"startTime":"0","endTime":"0","summary":"BOSTON, March 11, 2025----PureTech Health plc  , a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics,  a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert \"Bob\" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of Directors, such as FORTUNE 500 companies like BioMarin , where he also chairs the Audit Committee, and Henry Schein , a member of the S&P 500 index.The full text of the announcement from Seaport is as follows:. Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/puretech-founded-entity-seaport-therapeutics-110500549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BMRN","PSQ","PRTC","TQQQ","BAX","NQmain","LU0211328371.USD","LU2098885051.SGD","LU0310799852.SGD","LENZ","BK4566","LU0072461881.USD","BK4139","LU1267930490.SGD","LU1303367103.USD","NVIW.SI","IE00B7SZLL34.SGD","LU0211327993.USD","HSIC","BK4175","BK4588","SQQQ",".IXIC","USAW.SI","EMBC","QLD","BK4585","IE0002270589.USD","BK4198","BK4504","BK4082","IE00B19Z3581.USD","LU0162691827.USD","MNQmain","USJW.SI","TSYW.SI","QID","LU0006061336.USD","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2518719948","title":"Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2518719948","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518719948?lang=en_us&edition=fundamental","pubTime":"2025-03-11 17:03","pubTimestamp":1741683790,"startTime":"0","endTime":"0","summary":"As the craze of earnings season draws to a close, here’s a look back at some of the most exciting  results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad Genetics .Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine  and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth.The 10 therapeutics stocks we track reported a satisfactory Q4. As a group, revenues beat analysts’ consensus estimates by 2.6%.Thankfully, share prices of the companies have been resilient as they are up 5.2% on average since the latest earnings results.Founded in 1991, Myriad Genetics  provides genetic testing and precision medicine solutions, with a focus on identifying hereditary risks","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/winners-losers-q4-myriad-genetics-090310721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1496350171.SGD","MYGN","PSQ","LU1732800096.USD","LU1934455194.USD","LU2210150020.SGD","LU0198837287.USD","LU0689472784.USD","LU1989771016.USD","BMRN","LU0661504455.SGD","LU0882574055.USD","USJW.SI","LU0320765992.SGD","NVIW.SI","NQmain","BK4568","IE00BGHQF631.EUR","ABBV","MNQmain","LU0170899867.USD","TQQQ","USAW.SI","LU1037948897.HKD","TSYW.SI","IE0002141913.USD","LU0456855351.SGD","LU0820561818.USD","BK4112","NDAQ","LU1267930490.SGD","LU1093756325.SGD","SG9999001440.SGD","GILD","LU1066051498.USD","BK4139","QID","LU0965508806.USD","LU1989763690.USD","IE00B2B36J28.USD","LU1291159041.SGD","LU0738911758.USD","QLD","ABT","SQQQ",".IXIC","IE00BZ1G4Q59.USD","LENZ"],"gpt_icon":1},{"id":"2518042952","title":"Teladoc Boosts Weight Care Access With LillyDirect, Aids Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2518042952","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518042952?lang=en_us&edition=fundamental","pubTime":"2025-03-11 02:11","pubTimestamp":1741630260,"startTime":"0","endTime":"0","summary":"Teladoc Health, Inc. TDOC recently announced that it is expanding access to clinically responsible weight management treatments by integrating with Eli Lilly’s LillyDirect pharmacy partner, Gifthealth. This strategic move is set to benefit Teladoc’s Comprehensive Weight Care, as it enhances accessibility to FDA-approved Zepbound for eligible members seeking effective weight management solutions.The integration will streamline the prescription, fulfillment, and delivery process for Teladoc’s members who are prescribed Zepbound for obesity. With direct access to LillyDirect, members without insurance coverage for GLP-1 medications can now receive affordable and reliable weight management treatments at home. This offering is expected to drive higher patient engagement and sustained outcomes, supporting Teladoc’s mission to deliver evidence-based and affordable care.By capitalizing on the growing demand for GLP-1 medications and offering end-to-end support for weight management, Teladoc is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/teladoc-boosts-weight-care-access-181100483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BMRN","ENSG","IE0002270589.USD","IE00B19Z3B42.SGD","BK4534","LU1861559042.SGD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","OPCH","LU1861558580.USD","BK4196","BK4585","BK4139","BK4185","BK4548","BK4588","TDOC","BK4567","LU2065731478.USD","BK4566","BK4504","BK4167"],"gpt_icon":0},{"id":"2518565270","title":"INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2518565270","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518565270?lang=en_us&edition=fundamental","pubTime":"2025-03-10 22:52","pubTimestamp":1741618320,"startTime":"0","endTime":"0","summary":"IncyteINCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ruxolitinib cream 1.5% in adults with prurigo nodularis . The data readout from both studies was recently presented at the 2025American Academy of Dermatology Annual Meeting.PN is a chronic inflammatory skin condition causing intense itching and thickened red nodules, primarily on the arms, legs, and trunk. Affecting around 200,000 people in the United States, it is most common in individuals aged 40-69. Persistent scratching leads to nodules, significantly impacting sleep and overall quality of life.Please note that ruxolitinib cream 1.5%, a topical JAK1/2 inhibitor, is currently approved in the United States under the brand name Opzelura for treating nonsegmental vitiligo in patients aged 12 and older. It is also approved for short-term and non-continuous chronictreatment of mild to moderate atopic dermatitis in non-immunocompromised patients of the same age group w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/incy-opzelura-shows-superior-efficacy-145200413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","LU0289739699.SGD","LU1430594728.SGD","BMRN","LU1066053197.SGD","LU2468319806.SGD","LU0109394709.USD","BK4583","INCY","LU0566484027.USD","IE00B19Z3581.USD","CORT","LU1066051498.USD","LU2087621335.USD","LU2089984988.USD","IE00BKVL7J92.USD","BK4139","LU1839511570.USD","LU0234570918.USD","LU1585245621.USD","GILD","LU0058720904.USD","LU0889565916.HKD","BK4588","IE0002270589.USD","PN","IE00B7SZLL34.SGD","BK4585","IE00BSNM7G36.USD","LU1559883803.SGD","BK4566","IE00B19Z3B42.SGD","IE00B3T34201.USD","BK4578","BK4007","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4568","BK4550","LU1571399168.USD"],"gpt_icon":0},{"id":"2518277677","title":"EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2518277677","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518277677?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:41","pubTimestamp":1741614060,"startTime":"0","endTime":"0","summary":"Bristol Myers BMY announced that the European Commission  has approved the blockbuster immuno-oncology drug Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma , a type of liver cancer.This approval is based on results of phase III CheckMate -9DW clinical study demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of Lenvima  or Nexavar .HCC accounts for 90% of liver cancer cases worldwide, which is the third most frequent cause of cancer death.In August 2024, the FDA also accepted BMY’s supplemental biologics license application  for Opdivo plus Yervoy as a potential first-line treatment option for adult patients with unresectable HCC and assigned a target action date of April 21, 2025.We note that the FDA granted accelerated approval in 2020 for the combination of Opdivo plus Yervoy as a second-line treatment fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ec-approves-bristol-myers-opdivo-134100082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3581.USD","EC","BK4007","BK4532","GILD","LU2360032135.SGD","LU0306807586.USD","LU1074936037.SGD","LU1670710661.SGD","LU0109394709.USD","LU0321505439.SGD","LU1670710588.SGD","BK4566","LU0985481810.HKD","LU0882574055.USD","LU1093756168.USD","BMY","BK4126","LU0889565916.HKD","LU0289739699.SGD","BK4559","LU1032466523.USD","LU1261432733.SGD","IE00BZ1G4Q59.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU0225771236.USD","LU1430594728.SGD","LU2125154778.USD","LU1868837136.USD","BK4578","HCC","MYE","LU2089984988.USD","IE0009355771.USD","LU0320765992.SGD","LU1868837300.USD","LU1868836914.USD","BK4139","LU0306806265.USD","LU1323610961.USD","BMRN","LU1093756325.SGD","IE00BSNM7G36.USD","LU2242646821.SGD","LU0321505868.SGD","IE00B2B36J28.USD","LU0237698245.USD","LU0061475181.USD","BK4568"],"gpt_icon":0},{"id":"2518781082","title":"LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2518781082","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518781082?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:13","pubTimestamp":1741612380,"startTime":"0","endTime":"0","summary":"Eli LillyLLY and partner Incyte INCY announced that a late-stage study evaluating oral baricitinib in adolescent patients  with severe alopecia areata  showed clinically meaningful improvements in hair regrowth on the scalp, eyebrows and eyelashes at Week 36.The phase III BRAVE-AA-PEDS study enrolled 257 patients who were randomized to receive either a dose of baricitinib  or placebo.AA is an immune system disorder that leads to patchy hair loss on the scalp, face, and occasionally other parts of the body, with the potential to worsen over time. Around 40% of individuals with AA experience their first onset by the age of 20.LLY/INCY’s Phase III Alopecia Study Data in Detail. Lilly reported that 60% of patients receiving Olumiant 4 mg and 36.9% receiving Olumiant 2 mg experienced at least a 50% improvement in their condition, as measured by SALT score  compared to 5.7% on placebo. Additionally, 42.4% of patients receiving the 4 mg dose and 27.4% receiving the 2 mg dose achieved at least","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lly-incy-olumiant-shows-superior-131300949.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1280957306.USD","LU2237443978.SGD","BK4533","LU0061475181.USD","LU0114720955.EUR","BK4588","LU0109391861.USD","LU1366192091.USD","BK4583","IE0002270589.USD","SGXZ51526630.SGD","LU0823416689.USD","IE00B1BXHZ80.USD","LU2089984988.USD","BK4007","LU2491050071.SGD","LU0820561818.USD","IE00B4R5TH58.HKD","BK4566","LU1983299246.USD","LLY","LU2237443382.USD","LU1057294990.SGD","BMRN","SGXZ31699556.SGD","LU1430594728.SGD","LU1720051017.SGD","LU2361045086.USD","BK4599","LU1548497426.USD","GILD","IE00BSNM7G36.USD","LU2468319806.SGD","LU2491050154.USD","SG9999014914.USD","LU0354030511.USD","LU2237443549.SGD","INCY","LU0320765992.SGD","SG9999018857.SGD","LU0203201768.USD","LU1069344957.HKD","IE00BFTCPJ56.SGD","LU0106261372.USD","LU0466842654.USD","LU1551013342.USD","AA","IE00B2B36J28.USD","BK4578","GB00BDT5M118.USD"],"gpt_icon":1},{"id":"2518278158","title":"4 Discounted PEG Stocks Offering the Best Returns to Value Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2518278158","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518278158?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:44","pubTimestamp":1741610640,"startTime":"0","endTime":"0","summary":"With the market getting increasingly fickle on external shocks, investors are more focused on finding an investment strategy that emphasizes judging a stock's inherent potential. Needless to say, value investment is gaining popularity day by day. However, this apparently simple-to-understand investing strategy has historically shown dangerous outcomes a number of times because of people’s oversight of its basics.However, this simple value investment technique has some drawbacks, and not properly understanding the strategy may often lead to “value traps.” In such a situation, these value picks start to underperform over the long run when the temporary problems, which once drove the share price down, turn out to be persistent.However, for investors looking to escape such value traps, it is also vital to determine where the stock will be headed in the next 12 to 24 months. Warren Buffett advises these investors to focus on the earnings growth potential of a stock. This is where the import","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/4-discounted-peg-stocks-offering-124400327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","LU0321505868.SGD","BK4139","BK4158","IE00BMG7P819.SGD","LU0256331488.USD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","BK4208","IE00BN0W2V16.EUR","BK4532","IE0002270589.USD","LU0225771236.USD","LU0320765992.SGD","LU0321505439.SGD","LU2125154778.USD","IE00B19Z3B42.SGD","LU0225284248.USD","TAP","IE00BN0W2T93.GBP","LU2360032135.SGD","BK4585","IE00BD4GTT62.SGD","LU0985481810.HKD","IE00BN0W2W23.USD","LU0889565916.HKD","BK4211","LU0109394709.USD","JAZZ","LU0306807586.USD","BK4588","DVN","BK4007","IE00BD4GTW91.USD","BK4566","IE00BMG7P694.USD","LU0823416689.USD","ISBC","BMRN","LU2125154935.USD","IE00BD4GTV84.USD","BK4533","IE00BMG7P587.USD","IE00BMG7P926.USD","LU0306806265.USD","PEG"],"gpt_icon":0},{"id":"2517448646","title":"Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517448646","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517448646?lang=en_us&edition=fundamental","pubTime":"2025-03-08 16:37","pubTimestamp":1741423020,"startTime":"0","endTime":"0","summary":"Shares of Krystal Biotech KRYS have gained 15.8% in the past month compared with the industry’s growth of 4%. The stock has also outperformed the industry and the sector in this timeframe.Last month, KRYS reported fourth-quarter 2024 results. While earnings beat estimates, sales missed the same. Nonetheless, shares surged post the quarterly release, mostly due to the strong uptake of Vyjuvek and encouraging pipeline progress.Krystal recorded Vyjuvek sales of $290.5 million, up from $50.7 million in 2023.It has made steady progress, securing access and reimbursement for Vyjuvek since its launch in the United States.As of February 2025, Krystal secured more than 510 reimbursement approvals for Vyjuvek in the United States and continues to maintain strong access nationwide, including positive access determinations for 97% of lives covered under commercial and Medicaid plans.Krystal is looking to get Vyjuvek approved in other geographies as well.In October, Krystal Biotech filed a new drug","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/krystal-biotech-rises-15-8-083700261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZLL34.SGD","LU1430594728.SGD","LU1066051498.USD","IE00B3T34201.USD","LU0889565916.HKD","LU1585245621.USD","LU0320765992.SGD","BK4585","IE00BSNM7G36.USD","LU2089984988.USD","BK4139","LU2087621335.USD","IE00B19Z3581.USD","BK4568","BK4532","IE00BKVL7J92.USD","BK4588","LU2468319806.SGD","IE00BZ1G4Q59.USD","IE0002270589.USD","KRYS","BK4566","LU0289739699.SGD","IE00B19Z3B42.SGD","BMRN","LU1571399168.USD","LU1839511570.USD","LU0234570918.USD","GILD","BK4583","LU1066053197.SGD","LU0058720904.USD","LU0109394709.USD","BK4550","BK4578"],"gpt_icon":0},{"id":"2517245951","title":"PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2517245951","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517245951?lang=en_us&edition=fundamental","pubTime":"2025-03-07 23:58","pubTimestamp":1741363080,"startTime":"0","endTime":"0","summary":"Shares of Plus Therapeutics, Inc. PSTV were up a whopping 311.4% on March 6 after the company announced that the FDA has granted an Orphan Drug Designation  to its lead radiotherapeutic candidate, rhenium  obisbemeda, for treating leptomeningeal metastases  in patients with lung cancer. The stock continued to gain another 51.4% in after-hours trading following the news announcement.The FDA grants ODD to support the development of medicines for rare disorders that affect fewer than 200,000 people in the United States. The ODD makes the sponsor eligible to receive seven years of market exclusivity following a potential approval and tax credit for qualified clinical studies, as well as exemptions from certain FDA application fees, including the Prescription Drug User Fee Act  charge of $4.3 million in 2025.LM is a rare cancer complication in which the primary cancer spreads to the cerebrospinal fluid and leptomeninges that cover the brain and spinal cord.In the past year, shares of Plus T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pstv-stock-skyrockets-fdas-orphan-155800501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AMLX","BMRN","PSTV","BK4007","BK4566","IE0002270589.USD","IE00B19Z3B42.SGD","BK4139","IE00B7SZLL34.SGD","IE00B19Z3581.USD","XNCR"],"gpt_icon":1},{"id":"2517161326","title":"Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio","url":"https://stock-news.laohu8.com/highlight/detail?id=2517161326","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517161326?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:55","pubTimestamp":1741269300,"startTime":"0","endTime":"0","summary":"Relying solely on stock price movements without understanding the company’s fundamentals can cause investors to lose money. Investors must carefully review a company's financial health to make informed decisions, especially in today’s unpredictable market.While sales and earnings are often the go-to metrics, they can sometimes be misleading and may not show whether a company has the financial strength to cover its obligations. This is where the coverage ratio holds the key — a higher ratio signals that a company is more capable of meeting its financial commitments.Boot Barn Holdings, Inc. BOOT, Sterling Infrastructure, Inc. STRL, Deckers Outdoor Corporation DECK and BioMarin Pharmaceutical Inc. BMRN have impressive interest coverage ratios.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scoop-4-stocks-amazing-interest-135500715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BMRN","LU2065731478.USD","LU1559883803.SGD","EBIT","BK4567","BK4129","BK4566","BOOT","BK4139","LU0266013472.USD","IE00B7SZLL34.SGD","LU0566484027.USD","STRL","BK4588","BK4146","DECK","BK4585","IE0002270589.USD","IE00B19Z3581.USD","BK4094","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2517925010","title":"Teladoc Health Enhances Prism Platform for Better Virtual Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2517925010","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517925010?lang=en_us&edition=fundamental","pubTime":"2025-03-06 02:00","pubTimestamp":1741197600,"startTime":"0","endTime":"0","summary":"Teladoc Health, Inc. TDOC recently introduced new enhancements to its proprietary care delivery platform, Prism. The platform has enabled the company to achieve a competitive edge due to its extensive reach and capability to provide a wide range of high-quality virtual healthcare services.As a result of the new advancements, the platform now features improved data integration and administrative tools that automatically identify and highlight recommended screenings and diagnostic assessments. This ensures that Teladoc Health’s care teams have access to key insights, enabling them to address health gaps more effectively during patient interactions. Additionally, clinicians and health coaches can now seamlessly access member eligibility information and refer patients to Teladoc Health’s Connected Care Partners.Another significant advancement is the expanded closed-loop referral functionality, which now allows Teladoc Health care teams to connect patients with in-network community care pro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/teladoc-health-enhances-prism-platform-180000924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","IE0002270589.USD","BK4567","LU1861559042.SGD","OPCH","IE00B19Z3581.USD","BK4588","LU2065731478.USD","BK4196","BMRN","ENSG","LU1861558580.USD","BK4566","BK4548","BK4534","TDOC","BK4585","BK4167","IE00B19Z3B42.SGD","BK4139","IE00B7SZLL34.SGD","BK4185"],"gpt_icon":0},{"id":"2517302949","title":"Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term","url":"https://stock-news.laohu8.com/highlight/detail?id=2517302949","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517302949?lang=en_us&edition=fundamental","pubTime":"2025-03-05 22:40","pubTimestamp":1741185612,"startTime":"0","endTime":"0","summary":"Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.Why Investors Should Pay Attention to This Value Stock. Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks.San Rafael, CA-based BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for life-threatening severe medical conditions, mainly for children.BioMarin Pharmaceutical Inc.  : Free Stock Analysis Report. This article originally published on Zacks Investment Re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-biomarin-pharmaceutical-bmrn-top-144012325.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","BK4139","IE00B7SZLL34.SGD","IE0002270589.USD","BMRN","IE00B19Z3581.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2517911295","title":"BioMarin Pharmaceutical (BMRN) Receives a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2517911295","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517911295?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:18","pubTimestamp":1741180693,"startTime":"0","endTime":"0","summary":"In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price tar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/biomarin-pharmaceutical-bmrn-receives-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/biomarin-pharmaceutical-bmrn-receives-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4127","COWN","BK4207","TD","BMRN","IE0002270589.USD","IE00B7SZLL34.SGD","BK4139","BK4585","BK4566"],"gpt_icon":0},{"id":"2516418676","title":"Statutory Profit Doesn't Reflect How Good BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings Are","url":"https://stock-news.laohu8.com/highlight/detail?id=2516418676","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516418676?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:59","pubTimestamp":1741093198,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical Inc.  just reported healthy earnings but the stock price didn't move much. Our analysis suggests that investors might be missing some promising details.Check out our latest analysis for BioMarin Pharmaceutical. NasdaqGS:BMRN Earnings and Revenue History March 4th 2025. To properly understand BioMarin Pharmaceutical's profit results, we need to consider the US$86m expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. Assuming those unusual expenses don't come up again, we'd therefore expect BioMarin Pharmaceutical to produce a higher profit next year, all else being equal.Because unusual items detracted from BioMarin Pharmaceutical's earnings over","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/statutory-profit-doesnt-reflect-good-125958453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ",".IXIC","BMRN"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMRN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-19","symbol":"BMRN","fiscalQuarterEnding":"2024/12","expectedEps":0.55,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739941200000,"reportTimeType":"post","actualEps":0.72},{"market":"US","date":"2024-10-29","symbol":"BMRN","fiscalQuarterEnding":"2024/09","expectedEps":0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730174400000,"reportTimeType":"post","actualEps":0.74},{"market":"US","date":"2024-08-05","symbol":"BMRN","fiscalQuarterEnding":"2024/06","expectedEps":0.38,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722830400000,"reportTimeType":"post","actualEps":0.77},{"market":"US","date":"2024-04-24","symbol":"BMRN","fiscalQuarterEnding":"2024/03","expectedEps":0.37,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1713931200000,"reportTimeType":"post","actualEps":0.49},{"market":"US","date":"2024-02-22","symbol":"BMRN","fiscalQuarterEnding":"2023/12","expectedEps":0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1708578000000,"reportTimeType":"post","actualEps":0.26}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMRN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMRN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3448,"buy":0.4483,"hold":0.2069,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4483,"analysts":29,"updateTime":1740456000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BMRN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BMRN","date":"2025-04-02","current":30.364577,"percent":0.251429,"low":-742.431892,"twenty":18.236368,"median":112.870795,"eighty":244.603325,"high":1069.125802,"avg":162.28957,"sd":269.23278,"marketCap":12961392912},"quantilePoints":[{"date":"2020-04-03","current":-635.337762,"twenty":-142.381034,"median":-112.264026,"eighty":-74.453642,"marketCap":15151534944},{"date":"2020-04-09","current":-600.179539,"twenty":-143.5345,"median":-112.283523,"eighty":-74.522973,"marketCap":14313081639},{"date":"2020-04-17","current":-675.503116,"twenty":-144.16026,"median":-112.264026,"eighty":-74.453642,"marketCap":16109398307},{"date":"2020-04-24","current":-737.580882,"twenty":-145.315182,"median":-112.264026,"eighty":-74.453642,"marketCap":17589828874},{"date":"2020-05-01","current":139.717537,"twenty":-146.720429,"median":-112.32011,"eighty":-74.102444,"marketCap":15928637554},{"date":"2020-05-08","current":151.00669,"twenty":-146.720429,"median":-112.32011,"eighty":-70.459717,"marketCap":17215668691},{"date":"2020-05-15","current":148.690831,"twenty":-146.720429,"median":-112.264026,"eighty":-67.95747,"marketCap":16951646881},{"date":"2020-05-22","current":154.670823,"twenty":-146.720429,"median":-112.009509,"eighty":-65.875106,"marketCap":17633401828},{"date":"2020-05-29","current":169.010114,"twenty":-146.720429,"median":-111.583861,"eighty":-65.266721,"marketCap":19268167006},{"date":"2020-06-05","current":167.82046,"twenty":-146.720429,"median":-111.430067,"eighty":-53.616205,"marketCap":19132539364},{"date":"2020-06-12","current":167.693564,"twenty":-146.720429,"median":-111.166002,"eighty":-52.32921,"marketCap":19118072416},{"date":"2020-06-19","current":196.879731,"twenty":-146.720429,"median":-110.643992,"eighty":-51.800638,"marketCap":22445470566},{"date":"2020-06-26","current":196.72111,"twenty":-146.720429,"median":-110.454206,"eighty":-51.112661,"marketCap":22427386881},{"date":"2020-07-02","current":201.099035,"twenty":-146.720429,"median":-110.047751,"eighty":-50.787838,"marketCap":22926496603},{"date":"2020-07-10","current":199.956968,"twenty":-146.720429,"median":-109.640088,"eighty":-50.663322,"marketCap":22796294067},{"date":"2020-07-17","current":203.367308,"twenty":-146.720429,"median":-109.199968,"eighty":-50.401769,"marketCap":23185093307},{"date":"2020-07-24","current":195.023871,"twenty":-146.720429,"median":-109.08296,"eighty":-50.291122,"marketCap":22233891445},{"date":"2020-07-31","current":190.043188,"twenty":-146.720429,"median":-108.761911,"eighty":-50.018415,"marketCap":21666063717},{"date":"2020-08-07","current":176.02739,"twenty":-146.720429,"median":-108.266562,"eighty":-49.711244,"marketCap":21520756675},{"date":"2020-08-14","current":175.270889,"twenty":-146.720429,"median":-107.874867,"eighty":-49.409876,"marketCap":21428268381},{"date":"2020-08-21","current":111.294641,"twenty":-146.720429,"median":-107.54787,"eighty":-49.282149,"marketCap":13606660262},{"date":"2020-08-28","current":113.297144,"twenty":-146.720429,"median":-107.159772,"eighty":-49.094704,"marketCap":13851482218},{"date":"2020-09-04","current":112.733477,"twenty":-146.720429,"median":-106.448863,"eighty":-48.818303,"marketCap":13782569372},{"date":"2020-09-11","current":106.874302,"twenty":-146.720429,"median":-105.912505,"eighty":-48.569168,"marketCap":13066238463},{"date":"2020-09-18","current":117.74715,"twenty":-146.720429,"median":-105.43525,"eighty":-48.312221,"marketCap":14395531009},{"date":"2020-09-25","current":114.795312,"twenty":-146.720429,"median":-104.968329,"eighty":-48.052471,"marketCap":14034645311},{"date":"2020-10-02","current":111.220475,"twenty":-146.720429,"median":-104.968329,"eighty":-47.767481,"marketCap":13597592783},{"date":"2020-10-09","current":116.960982,"twenty":-146.720429,"median":-104.968329,"eighty":-47.469759,"marketCap":14299415723},{"date":"2020-10-16","current":117.554316,"twenty":-146.720429,"median":-104.968329,"eighty":-47.31175,"marketCap":14371955562},{"date":"2020-10-23","current":115.002979,"twenty":-146.720429,"median":-104.968329,"eighty":-47.07446,"marketCap":14060034255},{"date":"2020-10-30","current":110.40464,"twenty":-146.720429,"median":-104.968329,"eighty":-46.453512,"marketCap":13497850504},{"date":"2020-11-06","current":16.333756,"twenty":-145.315182,"median":-104.024299,"eighty":-46.24616,"marketCap":13916768073},{"date":"2020-11-13","current":16.516158,"twenty":-144.868574,"median":-103.498065,"eighty":-45.910184,"marketCap":14072179785},{"date":"2020-11-20","current":16.181659,"twenty":-144.868574,"median":-102.889101,"eighty":-45.353548,"marketCap":13787178208},{"date":"2020-11-27","current":17.129762,"twenty":-144.868574,"median":-102.47937,"eighty":-34.458654,"marketCap":14594985226},{"date":"2020-12-04","current":16.961447,"twenty":-144.868574,"median":-101.666821,"eighty":-33.817892,"marketCap":14451576789},{"date":"2020-12-11","current":16.93588,"twenty":-144.868574,"median":-101.332926,"eighty":-32.987662,"marketCap":14429793229},{"date":"2020-12-18","current":18.930091,"twenty":-144.868574,"median":-100.855221,"eighty":-31.786506,"marketCap":16128910912},{"date":"2020-12-24","current":18.88961,"twenty":-144.868574,"median":-100.530187,"eighty":-31.699842,"marketCap":16094420276},{"date":"2020-12-31","current":18.682945,"twenty":-144.868574,"median":-100.130791,"eighty":-31.545183,"marketCap":15918336499},{"date":"2021-01-08","current":19.145278,"twenty":-144.868574,"median":-99.499409,"eighty":-31.239921,"marketCap":16312255876},{"date":"2021-01-15","current":17.677318,"twenty":-144.868574,"median":-99.011614,"eighty":-31.142754,"marketCap":15061516470},{"date":"2021-01-22","current":18.746862,"twenty":-144.868574,"median":-98.307572,"eighty":-30.998361,"marketCap":15972795399},{"date":"2021-01-29","current":17.636837,"twenty":-144.868574,"median":-97.576033,"eighty":-30.940261,"marketCap":15027025834},{"date":"2021-02-05","current":18.156695,"twenty":-144.868574,"median":-97.576033,"eighty":-30.85726,"marketCap":15469958221},{"date":"2021-02-12","current":18.544458,"twenty":-144.868574,"median":-97.576033,"eighty":-30.741472,"marketCap":15800342215},{"date":"2021-02-19","current":17.419519,"twenty":-144.868574,"median":-97.521381,"eighty":-30.612592,"marketCap":14841865573},{"date":"2021-02-26","current":16.477433,"twenty":-144.868574,"median":-95.195111,"eighty":-30.351921,"marketCap":14072205552},{"date":"2021-03-05","current":16.549346,"twenty":-144.931156,"median":-92.988484,"eighty":-30.193594,"marketCap":14133621026},{"date":"2021-03-12","current":16.344954,"twenty":-144.931156,"median":-92.037344,"eighty":-30.118727,"marketCap":13959064533},{"date":"2021-03-19","current":16.645154,"twenty":-144.931156,"median":-90.941505,"eighty":-29.706846,"marketCap":14215444382},{"date":"2021-03-26","current":16.070302,"twenty":-144.868574,"median":-89.639785,"eighty":-29.214173,"marketCap":13724504246},{"date":"2021-04-01","current":16.570636,"twenty":-144.868574,"median":-88.5032,"eighty":-28.439397,"marketCap":14151803994},{"date":"2021-04-09","current":16.408826,"twenty":-144.931156,"median":-87.602744,"eighty":-27.75353,"marketCap":14013613437},{"date":"2021-04-16","current":16.904902,"twenty":-144.931156,"median":-86.817737,"eighty":-27.498326,"marketCap":14437276592},{"date":"2021-04-23","current":16.838842,"twenty":-144.931156,"median":-86.272203,"eighty":-27.151224,"marketCap":14380859669},{"date":"2021-04-30","current":17.900998,"twenty":-144.931156,"median":-85.694758,"eighty":15.913176,"marketCap":14232904679},{"date":"2021-05-07","current":17.874568,"twenty":-144.931156,"median":-85.610935,"eighty":16.023777,"marketCap":14211889902},{"date":"2021-05-14","current":17.681503,"twenty":-144.931156,"median":-85.219763,"eighty":16.210666,"marketCap":14058386140},{"date":"2021-05-21","current":17.950414,"twenty":-144.931156,"median":-84.959558,"eighty":16.297129,"marketCap":14272194951},{"date":"2021-05-28","current":17.766543,"twenty":-144.931156,"median":-84.679572,"eighty":16.395247,"marketCap":14126000892},{"date":"2021-06-04","current":17.902148,"twenty":-144.931156,"median":-84.297713,"eighty":16.432736,"marketCap":14233819010},{"date":"2021-06-11","current":18.862875,"twenty":-144.931156,"median":-84.279085,"eighty":16.501579,"marketCap":14997682966},{"date":"2021-06-18","current":18.823802,"twenty":-144.931156,"median":-84.279085,"eighty":16.577449,"marketCap":14966616728},{"date":"2021-06-25","current":19.488036,"twenty":-144.931156,"median":-84.279085,"eighty":16.648523,"marketCap":15494742764},{"date":"2021-07-02","current":19.644327,"twenty":-144.931156,"median":-84.279085,"eighty":16.690717,"marketCap":15619007714},{"date":"2021-07-09","current":19.219125,"twenty":-144.931156,"median":-84.185949,"eighty":16.765656,"marketCap":15280933954},{"date":"2021-07-16","current":18.120495,"twenty":-144.931156,"median":-83.841344,"eighty":16.854046,"marketCap":14407424455},{"date":"2021-07-23","current":17.706785,"twenty":-144.931156,"median":-83.683013,"eighty":16.951792,"marketCap":14078487823},{"date":"2021-07-30","current":16.8013,"twenty":-144.931156,"median":-83.422231,"eighty":17.027349,"marketCap":14066283248},{"date":"2021-08-06","current":17.110693,"twenty":-144.931156,"median":-82.965863,"eighty":17.063524,"marketCap":14325311683},{"date":"2021-08-13","current":16.431784,"twenty":-144.931156,"median":-82.965863,"eighty":17.063524,"marketCap":13756919692},{"date":"2021-08-20","current":16.455874,"twenty":-144.931156,"median":-82.965863,"eighty":17.063524,"marketCap":13777088440},{"date":"2021-08-27","current":18.288928,"twenty":-144.931156,"median":-82.965863,"eighty":17.151762,"marketCap":15311746815},{"date":"2021-09-03","current":18.604292,"twenty":-144.931156,"median":-82.965863,"eighty":17.265235,"marketCap":15575774062},{"date":"2021-09-10","current":17.077843,"twenty":-144.931156,"median":-82.965863,"eighty":17.275493,"marketCap":14297808844},{"date":"2021-09-17","current":17.029662,"twenty":-144.931156,"median":-82.965863,"eighty":17.275493,"marketCap":14257471348},{"date":"2021-09-24","current":17.213624,"twenty":-144.931156,"median":-82.965863,"eighty":17.308169,"marketCap":14411487243},{"date":"2021-10-01","current":16.89826,"twenty":-144.931156,"median":-82.965863,"eighty":17.308169,"marketCap":14147459995},{"date":"2021-10-08","current":17.044992,"twenty":-144.931156,"median":-82.965863,"eighty":17.308169,"marketCap":14270306006},{"date":"2021-10-15","current":16.620127,"twenty":-144.931156,"median":-82.965863,"eighty":17.308169,"marketCap":13914602631},{"date":"2021-10-22","current":16.14927,"twenty":-144.931156,"median":-82.965863,"eighty":17.308169,"marketCap":13520395283},{"date":"2021-10-29","current":913.742979,"twenty":-144.931156,"median":-82.965863,"eighty":17.356508,"marketCap":14544047003},{"date":"2021-11-05","current":967.9689,"twenty":-144.931156,"median":-82.965863,"eighty":17.405709,"marketCap":15407160981},{"date":"2021-11-12","current":942.70851,"twenty":-144.931156,"median":-82.965863,"eighty":17.560148,"marketCap":15005091360},{"date":"2021-11-19","current":1055.053805,"twenty":-144.931156,"median":-82.965863,"eighty":17.678992,"marketCap":16793291407},{"date":"2021-11-26","current":1010.184893,"twenty":-144.931156,"median":-82.965863,"eighty":17.719077,"marketCap":16079112949},{"date":"2021-12-03","current":956.780508,"twenty":-144.931156,"median":-82.965863,"eighty":17.763785,"marketCap":15229075350},{"date":"2021-12-10","current":979.157292,"twenty":-144.931156,"median":-82.965863,"eighty":17.780334,"marketCap":15585246612},{"date":"2021-12-17","current":997.497027,"twenty":-144.931156,"median":-82.965863,"eighty":17.854801,"marketCap":15877160172},{"date":"2021-12-23","current":1051.478133,"twenty":-144.931156,"median":-82.965863,"eighty":17.921454,"marketCap":16736377443},{"date":"2021-12-31","current":1019.0664,"twenty":-144.931156,"median":-82.965863,"eighty":18.068316,"marketCap":16220479893},{"date":"2022-01-07","current":971.77526,"twenty":-144.868574,"median":-82.756306,"eighty":18.102568,"marketCap":15467746814},{"date":"2022-01-14","current":1040.635774,"twenty":-144.868574,"median":-82.756306,"eighty":18.18902,"marketCap":16563799615},{"date":"2022-01-21","current":976.38903,"twenty":-144.868574,"median":-82.756306,"eighty":18.272526,"marketCap":15541184188},{"date":"2022-01-28","current":993.806011,"twenty":-144.868574,"median":-82.756306,"eighty":18.302,"marketCap":15818410273},{"date":"2022-02-04","current":1022.296039,"twenty":-144.868574,"median":-82.756306,"eighty":18.385092,"marketCap":16271886055},{"date":"2022-02-11","current":1048.594527,"twenty":-144.868574,"median":-82.756306,"eighty":18.50696,"marketCap":16690479084},{"date":"2022-02-18","current":978.811259,"twenty":-144.868574,"median":-82.756306,"eighty":18.612353,"marketCap":15579738809},{"date":"2022-02-25","current":-223.863547,"twenty":-146.720429,"median":-83.128851,"eighty":18.645295,"marketCap":14345176092},{"date":"2022-03-04","current":-219.184373,"twenty":-148.717362,"median":-83.543308,"eighty":18.645295,"marketCap":14045334603},{"date":"2022-03-11","current":-218.207922,"twenty":-159.853208,"median":-83.818061,"eighty":18.645295,"marketCap":13982763668},{"date":"2022-03-18","current":-234.549105,"twenty":-161.293219,"median":-83.967078,"eighty":18.645295,"marketCap":15029906670},{"date":"2022-03-25","current":-226.938537,"twenty":-162.185225,"median":-84.288399,"eighty":18.645295,"marketCap":14542221441},{"date":"2022-04-01","current":-227.656515,"twenty":-163.361234,"median":-84.633004,"eighty":18.645295,"marketCap":14588229481},{"date":"2022-04-08","current":-246.955768,"twenty":-164.641244,"median":-84.986921,"eighty":18.645295,"marketCap":15824925610},{"date":"2022-04-14","current":-238.225154,"twenty":-165.041247,"median":-85.857746,"eighty":18.645295,"marketCap":15265467837},{"date":"2022-04-22","current":-232.276832,"twenty":-165.973254,"median":-88.12096,"eighty":18.645295,"marketCap":14884299384},{"date":"2022-04-29","current":382.277246,"twenty":-166.445258,"median":-90.308931,"eighty":18.664196,"marketCap":15041462794},{"date":"2022-05-06","current":372.455987,"twenty":-166.445258,"median":-89.349626,"eighty":18.760072,"marketCap":14655025704},{"date":"2022-05-13","current":365.458317,"twenty":-166.445258,"median":-89.349626,"eighty":18.859197,"marketCap":14379688400},{"date":"2022-05-20","current":374.814577,"twenty":-166.445258,"median":-89.349626,"eighty":18.955948,"marketCap":14747829142},{"date":"2022-05-27","current":380.691624,"twenty":-166.445258,"median":-89.349626,"eighty":19.066512,"marketCap":14979073327},{"date":"2022-06-03","current":364.329924,"twenty":-166.445258,"median":-89.349626,"eighty":19.178673,"marketCap":14335289516},{"date":"2022-06-10","current":352.998976,"twenty":-166.445258,"median":-89.349626,"eighty":19.261875,"marketCap":13889450727},{"date":"2022-06-17","current":357.700614,"twenty":-166.445258,"median":-89.349626,"eighty":19.519294,"marketCap":14074446075},{"date":"2022-06-24","current":408.337255,"twenty":-166.509258,"median":-86.272203,"eighty":107.93637,"marketCap":16066845973},{"date":"2022-07-01","current":399.545192,"twenty":-166.509258,"median":-84.809963,"eighty":110.39574,"marketCap":15720904673},{"date":"2022-07-08","current":418.539809,"twenty":-166.509258,"median":-84.754081,"eighty":111.051374,"marketCap":16468285878},{"date":"2022-07-15","current":409.418632,"twenty":-166.509258,"median":-83.152135,"eighty":111.935442,"marketCap":16109394903},{"date":"2022-07-22","current":400.720602,"twenty":-166.509258,"median":-83.077626,"eighty":112.591077,"marketCap":15767153510},{"date":"2022-07-29","current":404.575945,"twenty":-166.509258,"median":-81.708522,"eighty":113.113211,"marketCap":15918849695},{"date":"2022-08-05","current":327.838991,"twenty":-166.509258,"median":-34.536978,"eighty":114.110012,"marketCap":17726254245},{"date":"2022-08-12","current":325.272938,"twenty":-166.509258,"median":-34.536978,"eighty":114.976279,"marketCap":17587507734},{"date":"2022-08-19","current":318.464838,"twenty":-166.509258,"median":-34.536978,"eighty":115.685314,"marketCap":17219393812},{"date":"2022-08-26","current":312.187472,"twenty":-166.509258,"median":-34.536978,"eighty":116.907582,"marketCap":16879976635},{"date":"2022-09-02","current":307.488024,"twenty":-166.509258,"median":-34.536978,"eighty":117.883617,"marketCap":16625877437},{"date":"2022-09-09","current":318.773561,"twenty":-166.509258,"median":-34.536978,"eighty":141.162306,"marketCap":17236086460},{"date":"2022-09-16","current":302.58276,"twenty":-166.509258,"median":-34.536978,"eighty":148.167383,"marketCap":16360649808},{"date":"2022-09-23","current":291.022801,"twenty":-166.509258,"median":-34.536978,"eighty":150.289725,"marketCap":15735602876},{"date":"2022-09-30","current":290.782684,"twenty":-166.509258,"median":-34.536978,"eighty":152.726136,"marketCap":15722619705},{"date":"2022-10-07","current":302.376944,"twenty":-166.509258,"median":-34.536978,"eighty":167.017841,"marketCap":16349521376},{"date":"2022-10-14","current":299.289715,"twenty":-166.509258,"median":-34.536978,"eighty":168.933976,"marketCap":16182594895},{"date":"2022-10-21","current":308.757218,"twenty":-166.509258,"median":-34.536978,"eighty":170.628042,"marketCap":16694502768},{"date":"2022-10-28","current":192.178834,"twenty":-166.509258,"median":-34.536978,"eighty":175.146289,"marketCap":16126110354},{"date":"2022-11-04","current":182.699459,"twenty":-166.509258,"median":-34.536978,"eighty":176.471621,"marketCap":15330676998},{"date":"2022-11-11","current":181.968573,"twenty":-166.509258,"median":-34.536978,"eighty":178.346579,"marketCap":15269346856},{"date":"2022-11-18","current":195.589638,"twenty":-166.509258,"median":-34.536978,"eighty":182.260927,"marketCap":16412317683},{"date":"2022-11-25","current":214.659129,"twenty":-166.509258,"median":-34.536978,"eighty":187.341695,"marketCap":18012476841},{"date":"2022-12-02","current":233.795065,"twenty":-166.509258,"median":-34.536978,"eighty":190.997361,"marketCap":19618211467},{"date":"2022-12-09","current":226.641237,"twenty":-166.509258,"median":-34.536978,"eighty":192.536436,"marketCap":19017919471},{"date":"2022-12-16","current":240.594523,"twenty":-166.509258,"median":-34.14536,"eighty":193.90401,"marketCap":20188767636},{"date":"2022-12-23","current":231.093,"twenty":-166.509258,"median":-33.835795,"eighty":195.798534,"marketCap":19391475791},{"date":"2022-12-30","current":229.210413,"twenty":-166.509258,"median":15.910621,"eighty":196.943179,"marketCap":19233504213},{"date":"2023-01-06","current":240.771708,"twenty":-166.509258,"median":15.99843,"eighty":199.747589,"marketCap":20203635549},{"date":"2023-01-13","current":249.653085,"twenty":-166.509258,"median":16.07919,"eighty":201.466427,"marketCap":20948889698},{"date":"2023-01-20","current":245.289915,"twenty":-166.509258,"median":16.188691,"eighty":202.812136,"marketCap":20582767336},{"date":"2023-01-27","current":259.730459,"twenty":-166.509258,"median":16.239185,"eighty":206.755441,"marketCap":21794502262},{"date":"2023-02-03","current":248.501386,"twenty":-166.509258,"median":16.333756,"eighty":220.240444,"marketCap":20852248263},{"date":"2023-02-10","current":242.432813,"twenty":-166.509258,"median":16.413891,"eighty":226.49506,"marketCap":20343022235},{"date":"2023-02-17","current":239.885785,"twenty":-166.509258,"median":16.442734,"eighty":229.440754,"marketCap":20129295983},{"date":"2023-02-24","current":226.065387,"twenty":-166.509258,"median":16.476957,"eighty":230.229225,"marketCap":18969598754},{"date":"2023-03-03","current":133.346847,"twenty":-166.509258,"median":16.516158,"eighty":230.229225,"marketCap":18876712940},{"date":"2023-03-10","current":119.234744,"twenty":-166.509258,"median":16.567292,"eighty":230.229225,"marketCap":16878989664},{"date":"2023-03-17","current":120.789579,"twenty":-166.509258,"median":16.617476,"eighty":230.229225,"marketCap":17099093629},{"date":"2023-03-24","current":119.564159,"twenty":-166.509258,"median":16.650384,"eighty":230.229225,"marketCap":16925621860},{"date":"2023-03-31","current":128.128926,"twenty":-166.445258,"median":16.685656,"eighty":229.9413,"marketCap":18138058956},{"date":"2023-04-06","current":127.246097,"twenty":-166.445258,"median":16.720301,"eighty":229.9413,"marketCap":18013084670},{"date":"2023-04-14","current":129.578349,"twenty":-166.509258,"median":16.77077,"eighty":230.229225,"marketCap":18343240618},{"date":"2023-04-21","current":127.575511,"twenty":-166.509258,"median":16.817229,"eighty":230.229225,"marketCap":18059716866},{"date":"2023-04-28","current":242.180022,"twenty":-166.509258,"median":16.855933,"eighty":231.407502,"marketCap":17343722249},{"date":"2023-05-05","current":250.17182,"twenty":-166.509258,"median":16.91578,"eighty":235.380867,"marketCap":17916054913},{"date":"2023-05-12","current":250.014562,"twenty":-166.573259,"median":16.941683,"eighty":237.019824,"marketCap":17904792857},{"date":"2023-05-19","current":241.732289,"twenty":-166.637259,"median":16.967171,"eighty":239.8282,"marketCap":17311657880},{"date":"2023-05-26","current":232.558885,"twenty":-166.637259,"median":17.014711,"eighty":240.585664,"marketCap":16654704583},{"date":"2023-05-30","current":231.916747,"twenty":-166.637259,"median":17.029662,"eighty":240.585664,"marketCap":16608717852},{"date":"2023-06-09","current":241.810918,"twenty":-166.73726,"median":17.061278,"eighty":241.008901,"marketCap":17317288908},{"date":"2023-06-16","current":251.194,"twenty":-166.74926,"median":17.112883,"eighty":241.385297,"marketCap":17989258281},{"date":"2023-06-23","current":250.591176,"twenty":-166.76126,"median":17.196104,"eighty":241.856963,"marketCap":17946087064},{"date":"2023-06-30","current":233.08308,"twenty":-166.76126,"median":17.241,"eighty":242.23058,"marketCap":16692244772},{"date":"2023-07-07","current":224.355242,"twenty":-166.76126,"median":17.308262,"eighty":242.23058,"marketCap":16067200635},{"date":"2023-07-14","current":224.643549,"twenty":-166.76126,"median":17.371372,"eighty":242.23058,"marketCap":16087847738},{"date":"2023-07-21","current":229.439928,"twenty":-166.76126,"median":17.48024,"eighty":242.23058,"marketCap":16431340462},{"date":"2023-07-28","current":226.871375,"twenty":-166.76126,"median":17.641098,"eighty":242.23058,"marketCap":16247393539},{"date":"2023-08-04","current":165.119407,"twenty":-166.76126,"median":17.695247,"eighty":242.23058,"marketCap":16510454583},{"date":"2023-08-11","current":171.085084,"twenty":-166.76126,"median":17.746561,"eighty":242.23058,"marketCap":17106968613},{"date":"2023-08-18","current":168.243389,"twenty":-166.76126,"median":17.778035,"eighty":242.23058,"marketCap":16822824706},{"date":"2023-08-25","current":175.281759,"twenty":-166.76126,"median":17.843539,"eighty":242.23058,"marketCap":17526598357},{"date":"2023-09-01","current":171.969585,"twenty":-166.76126,"median":17.901573,"eighty":242.23058,"marketCap":17195410756},{"date":"2023-09-08","current":170.162944,"twenty":-166.76126,"median":18.020515,"eighty":242.23058,"marketCap":17014762974},{"date":"2023-09-15","current":165.006492,"twenty":-166.76126,"median":18.09038,"eighty":242.23058,"marketCap":16499164096},{"date":"2023-09-22","current":162.352988,"twenty":-166.76126,"median":18.138595,"eighty":242.23058,"marketCap":16233837666},{"date":"2023-09-29","current":167.961101,"twenty":-166.76126,"median":18.255988,"eighty":242.23058,"marketCap":16794598490},{"date":"2023-10-06","current":164.272544,"twenty":-166.76126,"median":18.295251,"eighty":242.23058,"marketCap":16425775935},{"date":"2023-10-13","current":162.861106,"twenty":-166.76126,"median":18.372948,"eighty":242.23058,"marketCap":16284644855},{"date":"2023-10-20","current":155.427533,"twenty":-166.76126,"median":18.480739,"eighty":242.23058,"marketCap":15541354502},{"date":"2023-10-27","current":154.260745,"twenty":-166.76126,"median":18.544458,"eighty":242.382255,"marketCap":15424686142},{"date":"2023-11-03","current":102.060294,"twenty":-166.76126,"median":18.649124,"eighty":242.382255,"marketCap":15005006530},{"date":"2023-11-10","current":107.264835,"twenty":-166.76126,"median":18.746862,"eighty":242.382255,"marketCap":15770183276},{"date":"2023-11-17","current":111.736338,"twenty":-166.76126,"median":18.837592,"eighty":242.382255,"marketCap":16427588192},{"date":"2023-11-24","current":112.991947,"twenty":-166.76126,"median":18.922633,"eighty":242.382255,"marketCap":16612189000},{"date":"2023-12-01","current":116.69471,"twenty":-166.76126,"median":18.980092,"eighty":242.382255,"marketCap":17156573014},{"date":"2023-12-08","current":121.64027,"twenty":-166.76126,"median":19.115548,"eighty":242.331697,"marketCap":17883674154},{"date":"2023-12-15","current":125.073975,"twenty":-166.76126,"median":19.224871,"eighty":242.331697,"marketCap":18388500853},{"date":"2023-12-22","current":121.922141,"twenty":-166.76126,"median":19.421383,"eighty":242.331697,"marketCap":17925115152},{"date":"2023-12-29","current":124.446171,"twenty":-166.76126,"median":97.655587,"eighty":242.382255,"marketCap":18296200449},{"date":"2024-01-05","current":125.21491,"twenty":-166.76126,"median":106.724665,"eighty":242.432813,"marketCap":18409221351},{"date":"2024-01-12","current":122.998377,"twenty":-166.76126,"median":107.662485,"eighty":242.432813,"marketCap":18083344416},{"date":"2024-01-19","current":118.552498,"twenty":-166.79726,"median":109.532617,"eighty":242.575773,"marketCap":17429706862},{"date":"2024-01-26","current":116.91252,"twenty":-166.76126,"median":110.397223,"eighty":242.432813,"marketCap":17188595603},{"date":"2024-02-02","current":113.696625,"twenty":-166.76126,"median":111.153724,"eighty":242.432813,"marketCap":16715791494},{"date":"2024-02-09","current":112.940697,"twenty":-166.76126,"median":111.821225,"eighty":242.432813,"marketCap":16604654273},{"date":"2024-02-16","current":113.132882,"twenty":-166.76126,"median":112.099749,"eighty":242.432813,"marketCap":16632909499},{"date":"2024-02-23","current":101.214924,"twenty":-166.70126,"median":112.294622,"eighty":242.432813,"marketCap":16968175915},{"date":"2024-03-01","current":97.103598,"twenty":-165.901253,"median":112.199476,"eighty":242.382255,"marketCap":16278932666},{"date":"2024-03-08","current":96.664673,"twenty":-164.837246,"median":112.199476,"eighty":242.382255,"marketCap":16205349173},{"date":"2024-03-15","current":94.976502,"twenty":-164.11324,"median":112.199476,"eighty":242.382255,"marketCap":15922335740},{"date":"2024-03-22","current":94.661377,"twenty":-162.221226,"median":112.199476,"eighty":242.382255,"marketCap":15869506566},{"date":"2024-03-28","current":99.72589,"twenty":-162.081225,"median":112.199476,"eighty":242.382255,"marketCap":16718546865},{"date":"2024-04-05","current":97.790121,"twenty":-160.981216,"median":112.294622,"eighty":242.432813,"marketCap":16394024795},{"date":"2024-04-12","current":103.533211,"twenty":-131.648601,"median":112.294622,"eighty":242.432813,"marketCap":17356825158},{"date":"2024-04-19","current":101.959724,"twenty":-125.404689,"median":112.294622,"eighty":242.432813,"marketCap":17093037852},{"date":"2024-04-26","current":75.899547,"twenty":-124.450186,"median":112.199476,"eighty":242.382255,"marketCap":15593941332},{"date":"2024-05-03","current":77.447263,"twenty":-123.068927,"median":112.199476,"eighty":242.382255,"marketCap":15911927491},{"date":"2024-05-10","current":75.524945,"twenty":-121.619256,"median":112.199476,"eighty":242.382255,"marketCap":15516977501},{"date":"2024-05-17","current":71.135034,"twenty":-119.850332,"median":112.199476,"eighty":242.382255,"marketCap":14615048436},{"date":"2024-05-24","current":70.146149,"twenty":-118.560287,"median":112.199476,"eighty":242.382255,"marketCap":14411877047},{"date":"2024-05-31","current":68.833797,"twenty":-117.48525,"median":112.199476,"eighty":242.382255,"marketCap":14142247727},{"date":"2024-06-07","current":74.720898,"twenty":-116.644766,"median":112.199476,"eighty":242.382255,"marketCap":15351782072},{"date":"2024-06-14","current":77.853908,"twenty":-111.266324,"median":112.294622,"eighty":242.432813,"marketCap":15995474604},{"date":"2024-06-21","current":78.288278,"twenty":-109.731954,"median":112.389767,"eighty":242.575773,"marketCap":16084718112},{"date":"2024-06-28","current":77.170006,"twenty":-106.985723,"median":112.453746,"eighty":243.004654,"marketCap":15854963550},{"date":"2024-07-05","current":74.836422,"twenty":-105.324301,"median":112.453746,"eighty":243.004654,"marketCap":15375517047},{"date":"2024-07-12","current":77.548924,"twenty":15.962481,"median":112.453746,"eighty":243.004654,"marketCap":15932814269},{"date":"2024-07-15","current":78.574777,"twenty":15.978924,"median":112.453746,"eighty":243.004654,"marketCap":16143580851},{"date":"2024-08-02","current":78.205101,"twenty":16.215911,"median":112.851011,"eighty":244.594819,"marketCap":16067628929},{"date":"2024-08-09","current":65.219671,"twenty":16.277249,"median":112.851011,"eighty":244.594819,"marketCap":16734650053},{"date":"2024-08-16","current":66.1694,"twenty":16.362887,"median":112.851011,"eighty":244.594819,"marketCap":16978340065},{"date":"2024-08-23","current":66.792659,"twenty":16.42422,"median":112.851011,"eighty":244.594819,"marketCap":17138261636},{"date":"2024-08-30","current":67.794327,"twenty":16.45237,"median":112.851011,"eighty":244.594819,"marketCap":17395278446},{"date":"2024-09-06","current":63.156978,"twenty":16.479702,"median":112.851011,"eighty":244.594819,"marketCap":16205385808},{"date":"2024-09-13","current":62.607916,"twenty":16.537344,"median":112.851011,"eighty":244.594819,"marketCap":16064502520},{"date":"2024-09-20","current":52.98449,"twenty":16.577992,"median":112.851011,"eighty":244.594819,"marketCap":13595237319},{"date":"2024-09-27","current":52.116378,"twenty":16.619251,"median":112.851011,"eighty":244.594819,"marketCap":13372489417},{"date":"2024-10-04","current":50.573069,"twenty":16.6558,"median":112.851011,"eighty":244.594819,"marketCap":12976493147},{"date":"2024-10-11","current":51.827008,"twenty":16.697708,"median":112.851011,"eighty":244.594819,"marketCap":13298240116},{"date":"2024-10-18","current":51.545057,"twenty":16.760117,"median":112.851011,"eighty":244.594819,"marketCap":13225894644},{"date":"2024-10-25","current":52.227675,"twenty":16.799788,"median":112.851011,"eighty":244.594819,"marketCap":13401046840},{"date":"2024-10-31","current":39.424418,"twenty":16.832825,"median":112.851011,"eighty":244.594819,"marketCap":12706135252},{"date":"2024-11-08","current":39.584187,"twenty":16.900012,"median":112.851577,"eighty":244.597655,"marketCap":12757627091},{"date":"2024-11-15","current":38.791793,"twenty":16.930391,"median":112.851577,"eighty":244.597655,"marketCap":12502245849},{"date":"2024-11-22","current":37.520416,"twenty":16.956385,"median":112.851577,"eighty":244.597655,"marketCap":12092492365},{"date":"2024-11-29","current":39.046069,"twenty":16.983395,"median":112.851577,"eighty":244.597655,"marketCap":12584196546},{"date":"2024-12-06","current":39.122943,"twenty":17.042364,"median":112.851577,"eighty":244.597655,"marketCap":12608972338},{"date":"2024-12-13","current":39.182077,"twenty":17.063524,"median":112.851577,"eighty":244.597655,"marketCap":12628030640},{"date":"2024-12-20","current":38.43699,"twenty":17.120949,"median":112.851577,"eighty":244.597655,"marketCap":12387896040},{"date":"2024-12-27","current":39.631494,"twenty":17.201205,"median":112.851577,"eighty":244.597655,"marketCap":12772873732},{"date":"2025-01-03","current":39.318084,"twenty":17.236838,"median":112.851577,"eighty":244.597655,"marketCap":12671864733},{"date":"2025-01-10","current":40.435714,"twenty":17.313842,"median":112.852143,"eighty":244.60049,"marketCap":13032066634},{"date":"2025-01-17","current":36.219472,"twenty":17.376382,"median":112.852143,"eighty":244.60049,"marketCap":11673209730},{"date":"2025-01-24","current":36.77533,"twenty":17.466817,"median":112.852143,"eighty":244.60049,"marketCap":11852357765},{"date":"2025-01-31","current":37.774691,"twenty":17.638541,"median":112.852143,"eighty":244.60049,"marketCap":12174443062},{"date":"2025-02-07","current":38.046707,"twenty":17.688324,"median":112.852143,"eighty":244.60049,"marketCap":12262111249},{"date":"2025-02-14","current":38.094014,"twenty":17.743365,"median":112.852143,"eighty":244.60049,"marketCap":12277357890},{"date":"2025-02-21","current":30.715125,"twenty":17.776197,"median":112.852143,"eighty":244.60049,"marketCap":13111027516},{"date":"2025-02-28","current":30.891957,"twenty":17.826301,"median":112.852143,"eighty":244.60049,"marketCap":13186509834},{"date":"2025-03-07","current":31.826045,"twenty":17.900998,"median":112.870795,"eighty":244.603325,"marketCap":13585233872},{"date":"2025-03-14","current":31.553417,"twenty":18.033156,"median":112.870795,"eighty":244.603325,"marketCap":13468859871},{"date":"2025-03-21","current":32.000349,"twenty":18.097039,"median":112.870795,"eighty":244.603325,"marketCap":13659636923},{"date":"2025-03-28","current":32.550076,"twenty":18.156695,"median":112.870795,"eighty":244.603325,"marketCap":13894292697},{"date":"2025-04-02","current":30.364577,"twenty":18.236368,"median":112.870795,"eighty":244.603325,"marketCap":12961392912}],"updateTime":1743723187334}}}